However, the combination of TMECG with methotrexate (MTX), which is able to upregulate MITF-M and therefore tyrosinase expression in melanoma cells, leads to the death of the tumor cells regardless of the mutation status of BRAF, MEK or p53 [42]. This evidence concerns the gene MAP2K7 and neoplasm.